DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 204275/S-001

SUPPLEMENT APPROVAL

GlaxoSmithKline
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709

Attention: Christopher Stotka, PharmD.
Director, Regulatory Affairs

Dear Dr. Stotka:

Please refer to your Supplemental New Drug Application (sNDA) dated June 30, 2014, received June 30, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Breo Ellipta (fluticasone furoate/vilanterol) inhalation solution.

We acknowledge receipt of your amendments dated July 8, August 4, September 11, 23, 25, and 30, October 14 (2), 17, and 23, and November 7, and 12, 2014; and January 16, and 19, February 12, and April 2, 22, and 29, 2015.

This Prior Approval supplemental new drug application proposes the daily treatment of asthma in patients aged 18 years and older and the addition of a 200 mcg/25mcg product.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use in patients 18 years and older as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content

of labeling must be identical to the enclosed labeling (text for the package insert, text for the instructions for use and, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008). Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "Final Printed Carton and Container Labels for approved NDA 204275/S-001." Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to less than 5 years because the product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients of this age, and is not likely to be used in a substantial number of pediatric patients in this age group.

We are deferring submission of your pediatric studies for ages 5 to 11 years for this application because this product is ready for approval for use in adults and the pediatric studies have not been completed.

Your deferred pediatric studies required by section 505B(a) of the FDCA are required postmarketing studies. The status of these postmarketing studies must be reported annually according to 21 CFR 314.81 and section 505B(a)(3)(B) of the FDCA. These required studies are listed below.

2904-1 Conduct a randomized, double blind, double-dummy, active- and placebo controlled, 4-period crossover dose-ranging study with vilanterol inhalation powder in children 5 to 11 years of age with asthma. Each treatment period will be of one-week duration with at least one-week washout period between treatment periods.

Final Protocol Submission:	March 2016
Study Completion:	June 2017
Final Report Submission:	December 2017

2904-2 Conduct a 12 week randomized, double-blind, active controlled, safety and efficacy study with fluticasone furoate/vilanterol inhalation powder in children 5 to 11 years of age with asthma.

Final Protocol Submission:	June 2018
Study Completion:	May 2021
Final Report Submission:	November 2021

2904-3 Conduct a 52 week randomized, double blind, active comparator, safety study with fluticasone furoate/vilanterol inhalation powder in children 5 to 11 years of age with asthma.

Final Protocol Submission:	June 2018
Study Completion:	March 2022
Final Report Submission:	September 2022

We remind you of the the following deferred pediatric studies required under PREA, for Breo Ellipta, to assess fluticasone furoate inhalation powder. These studies were also listed in the August 20, 2014, Approval letter for NDA 205625 Arnuity Ellipta (fluticasone furoate inhalation powder) 100 mcg and 200 mcg.

2765-1: Conduct a 12-week, randomized, double-blind, double-dummy, parallel group, placebo-controlled, dose-ranging, efficacy, and safety study in children 5-11 years of age with asthma. The final study report will be submitted as a supplement with the results of the knemometry and Hypothalamic Pituitary Adrenal (HPA) axis studies.

Final Report Submission: June 2017

2765-2: Conduct a 2-week randomized, double-blind, placebo-controlled, 2-way crossover, knemometry growth rate study in children 5-11 years of age with asthma.

Final Protocol Submission: September 2015
Study Completion: March 2016
Final Report Submission: June 2017

2765-3: Conduct a 52-week, randomized, double-blind, parallel group, active controlled, growth study in females 5-<8 years of age and males 5-<9 years of age with asthma.

Final Protocol Submission: October 2016
Study Completion: October 2021
Final Report Submission: June 2022

2765-4: Conduct a 6-week, randomized, double-blind, parallel group, placebo-controlled, HPA-axis study in children 5-11 years of age with asthma.

Final Protocol Submission: September 2015
Study Completion: November 2016
Final Report Submission: June 2017

Submit the protocols to your IND 77855, with a cross-reference letter to this NDA.

Reports of these required pediatric postmarketing studies must be submitted as a new drug application (NDA) or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

We note that you have fulfilled the pediatric study requirement for ages 12 to17 years olds for this application.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Angela Ramsey, Senior Program Management Officer, at (301) 796-2284.

Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, M.D., Ph.D.
Director
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BADRUL A CHOWDHURY
04/30/2015